Previous studies have demonstrated that cyclin D1, an upstream regulator of the Rb/E2F pathway, is an essential component of the ErbB2/Ras (but not the Wnt/Myc) oncogenic pathway in the mammary epithelium. However, the role of specific E2fs for ErbB2/Ras-mediated mammary tumorigenesis remains unknown. Here we show that in the majority of mouse and human primary mammary carcinomas with ErbB2/HER2 over-expression, E2f3a is up-regulated, raising the possibility that E2F3a is a critical effector of the ErbB2 oncogenic signaling pathway in the mammary gland. We examined the consequence of ablating individual E2fs in mice on ErbB2-triggered mammary tumorigenesis in comparison to a comparable Myc-driven mammary tumor model. We found that loss of E2f1 or E2f3 led to a significant delay on tumor onset in both oncogenic models, whereas loss of E2f2 accelerated mammary tumorigenesis driven by Myc-over- 
Introduction
Uncontrolled cell growth is one of the hallmarks of cancer, and typically involves genetic or epigenetic alterations to genes that directly regulate the cell cycle and cellular proliferation.
(1) Previous studies have led to the delineation of a pathway controlling the progression of cells out of quiescence, through G 1 , and into S phase that involves the activation of cyclindependent kinases (CDKs), phosphorylation and inactivation of the retinoblastoma tumor suppressor (Rb), and the subsequent release of E2F transcription factors. (2) (3) (4) It is now evident, from studies using both in vitro cell culture systems and in vivo mouse models, that the tumor suppressor function of Rb is largely mediated through its interaction with members of the E2F family and its regulation of E2F-dependent transcriptional activation or repression. (5, 6) The mammalian E2F family of transcription factors consists of eight known genes (E2F1-8) encoding nine E2F proteins, with the E2f3 locus encoding two distinct isoforms, E2F3a and 3b. (7) (8) (9) (10) Based on their structure and function, E2Fs can be divided into two broad groups. The first group, consisting of E2F1, E2F2, and E2F3a, is collectively called activators, since their primary function is to activate genes that are required for entry of cells into S phase. The remaining E2Fs form the repressor group, whose primary function is to repress genes in quiescent or terminally differentiated cells. Early studies using mouse embryonic fibroblasts (MEFs) suggest that the E2F activator subclass is critical for normal cellular proliferation since over-expression of any of the three E2f activators is sufficient to induce quiescent cells to enter the cell cycle. Using MEFs lacking the entire E2F activator subclass, we previously showed that E2F activators are essential for normal cellular proliferation. (11) In addition, we also demonstrated that E2F1, E2F2, and E2F3 are required for aberrant cell growth under oncogenic insults since loss of the three E2Fs prevents Myc and Ras oncogene-induced cellular transformation in primary MEFs, (12) suggesting that E2F1-3 are also required for tumor initiation and/or progression in vivo.
Considering the central role of the Rb/E2F pathway in the control of cell cycle, it is not surprising to find genetic alterations in this pathway in essentially all human malignancies. (13) Moreover, targeted deletion of Rb in mice leads to hyperplasia and carcinomas, (14) (15) (16) (17) (18) further supporting an important role of Rb in tumor suppression. Alterations of E2F activators may also contribute to aberrant cell growth and cancer development, through either over-expression/amplification or disruption of their association with Rb. Overexpression of E2F1 is associated with several types of human cancers. (19, 20) More recently, it has been found that E2F3 is up-regulated in 67% of prostate cancers, and patients with E2F3 over-expression have poorer overall survival and reduced cause-specific survival. (21) Consistent with an important role of E2F3 in human cancer development, E2F3 is either up-regulated or amplified in several other cancer types. (22) (23) (24) (25) (26) (27) In mice, forced expression of E2f1, E2f2 or E2f3 leads to hyperplasia or neoplasia. (28) (29) (30) (31) (32) However, lossof-function studies in mice do not always support an oncogenic role of E2Fs. For example, deletion of E2f3 in Rb +/− mice reduces the incidence of pituitary tumors but enhances the metastasis of thyroid tumors. (33) In addition, loss of E2f2 accelerates Myc-induced lymphomagenesis while the role of E2f1 in this process remains controversial. (34) (35) (36) Furthermore, inactivation of E2f1 or E2f2 enhanced Myc-induced skin tumorigenesis. (37, 38) Nonetheless, collectively these data suggest that E2F activators not only play important roles in regulating normal cellular proliferation, but also contribute to aberrant cell growth and cancer development.
Early studies using MEFs have established a functional link between the Myc or ErbB2/Ras pathway and the Rb/E2F pathway, as Myc or Ras elicits mitogenic signals that activate the cyclin/CDK complexes, leading to the release of E2F activities that promote cell growth. (39) In addition, in MEFs the ability of Myc to induce proliferation or apoptosis is dependent on specific E2F activities. (40) The importance of E2Fs in mediating Myc or Ras signaling is further highlighted by the recent finding that E2f1-3 are essential for Myc/Rasinduced cellular transformation. (12) Finally, recent studies using in vivo mouse models demonstrated that E2f1 and E2f2 mediate Myc-induced lymphomogenesis as loss of E2f1 delays Myc-induced T cell lymphomas,(34) whereas loss of E2f2 accelerates Myc-induced T cell and B cell lymphomas. (35, 36) To understand the in vivo role of E2F1, E2F2 and E2F3 in regulating oncogene-induced mammary tumorigenesis, we sought to determine whether loss of E2f1, E2f2, or E2f3 in mice impacts on mammary tumorigenesis triggered by the mammary epithelium-specific over-expression of ErbB2/HER2/Neu or Myc, two oncogenes that are over-expressed in up to 30% of human breast cancer patients. Here we show that deletion of E2f1, E2f2, or E2f3 have differential effects on the development of ErbB2-and Myc-induced mammary tumors, raising the possibility that E2Fs, particularly E2F3, are important downstream effectors in Myc-and ErbB2-mediated oncogenic signaling in mammary glands.
Results

E2F activators are up-regulated in ErbB2-overexpressing human primary mammary carcinomas
Considering that ErbB2-or Ras-mediated mammary tumorigenesis in mice is strictly dependent on Cyclin D1,(41) which has been shown to activate E2f activators through phosphorylation and inactivation of Rb, we decided to assess whether E2F activators are relevant factors in human breast cancers. To this end, we collected a set of 12 human primary mammary carcinomas and measured mRNA transcript levels of E2Fs by qPCR. Mammary tissues from six tissue reduction patients with normal breast pathology were used as controls. Among the 12 mammary tumor samples, four had elevated levels (20 to 80 folds) of HER2 transcripts (Figure 1a) . Importantly, tumor samples with HER2 overexpression also had much higher levels of E2F activators, E2F1, E2F2, and E2F3a than both normal controls and tumor samples without HER2 over-expression. Furthermore, there were marginal increases in E2F3b transcripts in tumor samples with HER2 over-expression than in the controls, but substantially lower levels of E2F3b transcripts in tumor samples without HER2 over-expression.
Up-regulation of E2fs in ErbB2-induced and Myc-induced mouse mammary carcinomas
We next asked whether E2f1, E2f2, and E2f3a are also preferentially up-regulated in mouse mammary carcinomas with ErbB2 over-expression. To this end, we collected a set of 10 primary mammary carcinomas from MMTV-ErbB2 transgenic mice that carry the ErbB2 oncogene driven by the MMTV promoter, (42) and that had gone through two pregnancy/ lactation cycles. We then used qPCR to evaluate expression levels of various E2fs compared to those of normal mammary glands from wild-type littermate control mice. In parallel, we also carried out the same analysis with a set of nine primary mammary carcinomas from Wap-Myc mice where the Myc oncogene is driven by the Wap (Whey Acidic Protein) promoter. (43) As shown in Figure 1b , while there was a moderate increase (~2-3 fold) of E2f3a and a marginal increase of E2f2 in Wap-Myc tumors compared to normal controls, there was essentially no change in expression levels of E2f1 or E2f3b. Importantly, in almost all MMTV-ErbB2 tumors, there were substantial increases (~15 fold) in E2f3a expression, and moderate increases (~5 fold) in E2f1 expression.
E2F3 is not required for normal mammary gland development
The data presented above suggest that E2F activators are important mediators of mammary carcinomas with ErbB2 over-expression in both mice and humans. Since E2f3a exhibited the largest up-regulation in those mammary carcinomas, we initially focused on understanding how inactivation of E2f3 impacts on ErbB2-or Myc-induced mammary carcinomas in mice. We first determined whether E2F3 is required for normal mouse mammary gland development by using a Wap-Cre transgene (44) to delete an E2f3 conditional knockout allele (E2f3 loxP )(11) specifically in mammary epithelial cells. Consistent with previous report,(44) X-gal staining on whole mount mammary glands from the Rosa26 +/LSL-lacZ reporter mice (45) confirmed that Cre expression under the control of the Wap promoter is restricted to the mammary epithelium ( Figure 2a ). However, Wap-Cre-mediated recombination and subsequent activation of the lacZ gene was incomplete as evidenced by the partial, patchy blue staining in mammary epithelial ducts of day 16.5 pregnant females.
To determine whether Wap-Cre-mediated deletion of E2f3 in mammary epithelial cells affects mammary gland development, we examined the mammary gland structures of monoparous female mice with either 16.5 days of pregnancy or one day of lactation. As shown in Figure 2b and 2c, Carmine-stained whole mount mammary glands of WapCre;E2f3 −/loxP mice displayed similar lobuloalveolar structures and ductal branching patterns as those of control E2f3 −/loxP mice. Furthermore, analysis of H&E-stained sections of mammary glands did not show obvious differences between Wap-Cre;E2f3 −/loxP mice and control mice (Figure 2b and 2c). These data suggest that Wap-Cre-mediated deletion of E2f3 in mammary epithelial cells did not affect the mammary gland development in both pregnant females and lactating females. However, the patchy staining shown in Figure 2a suggests incomplete deletion of E2f3 in mammary epithelium of Wap-Cre;E2f3 −/loxP mice. Therefore, our data do not completely rule out the possibility that E2F3 is required for the normal mammary gland development. However, considering that E2f3 germline knockout female mice in a mixed genetic background are fertile and are capable of nursing pups, it is unlikely that E2F3 is required for normal mammary gland development. Lastly, it is important to note that E2f1 or E2f2 knockout female mice are also fertile and can nurse their pups normally. Therefore, neither E2F1 nor E2F2 is likely required for normal mammary gland development.
Inactivation of E2f1, E2f2, or E2f3 alters Myc-and ErbB2-mediated mammary tumorigenesis
To understand the in vivo roles of individual E2Fs in Myc-or ErbB2-mediated mammary tumorigenesis, we determined whether inactivation of E2f1, E2f2, or E2f3 affects Myc-or ErbB2-induced mammary carcinomas. To this end, we interbred E2f1 +/− , E2f2 +/− , or E2f3 −/loxP mice with one of the two parents containing either oncogenic allele to generate cohorts of mice over-expressing either oncogene and with or without E2f1, E2f2, or E2f3. We monitored mammary tumor onset in all cohorts of mice by manual palpation bi-weekly, and evaluated tumor onset by using standard Kaplan-Meier tumor-free curves as well as t 50 , or the number of days required for 50% of the mice to develop tumors. Tumor-free curves revealed no significant difference in tumor initiation among E2f wild-type (including E2f3 +/loxP and E2f3 loxP/loxP ) mice generated from intercrosses of E2f1 +/− , E2f2 +/− , or E2f3 −/loxP mice over-expressing ErbB2 or Myc (p = 0.598 and 0.117 for ErbB2-and Mycover-expressing tumor mice, respectively). Therefore, for tumor initiation analyses we pooled all E2f wild-type mice (labeled as +/+ or E2f +/+ ) over-expressing either oncogene. As shown in Figure 3a and 3b, genetic deletion of individual E2fs had various impacts on mammary carcinogenesis. Specifically, in mice with ErbB2 over-expression, while deletion of E2f2 had no significant impact on tumor initiation (p = 0.261), loss of E2f1 or E2f3 led to significant delays of tumor onsets (p < 0.001 in both cases), with t 50 being increased by 34 days and 29 days, respectively. It is interesting to note that MMTV-ErbB2;E2f1 +/− mice also had a significant delay of tumor onset compared to MMTV-ErbB2 mice (p < 0.001), with t 50 being increased by 14 days. Consistent with important roles of E2F1 and E2F3 in mediating oncogene-triggered mammary tumorigenesis, loss of E2f1 or E2f3 also led to significant delays of tumor onset in mice with Myc over-expression (p = 0.004 and 0.003, respectively), with t 50 being increased by 10 days and 21 days, respectively (Figure 3a and 3b) . On the other hand, loss of E2f2 in Myc-over-expressing mice led to a significant acceleration of tumor onset (p < 0.001), with t 50 being reduced by 9 days. Consistent with specific roles of E2F1-3 on oncogene-triggered mammary tumorigenesis, MMTV-ErbB2;WapCre;E2f3 −/loxP mice had a significantly lower average number of tumors compared to MMTV-ErbB2 mice (p < 0.001), and Wap-Myc;E2f2 −/− mice had a significantly higher average number of tumors compared to Wap-Myc mice (p < 0.01) (Figure 3c ). In addition, MMTV-ErbB2;E2f1 −/− mice, MMTV-ErbB2;E2f2 −/− mice, and Wap-Myc;WapCre;E2f3 −/loxP mice all had moderate but statistically non-significant decreases in average numbers of tumors than control mice (Figure 3c ).
To determine whether loss of various E2fs also affects tumor growth, we measured tumor volumes once a week for six consecutive weeks. As shown in Figure 3d, (Figure 3d ).
Most mammary tumors from Wap-Cre;E2f3 −/loxP mice retained the E2f3 loxP allele As shown in Figure 3a and 3b, although there was only a marginal difference on tumor initiation between MMTV-ErbB2;Wap-Cre;E2f3 +/loxP mice and the control mice ( Figure  4A , p = 0.047; t 50 of 177 days vs. 171 days), there was a significant delay of tumor onset in MMTV-ErbB2;E2f3 −/loxP mice than in the control mice (Figure 4a, Figure 4c and 4d, in tumors derived from MMTVErbB2;Wap-Cre;E2f3 +/loxP mice and Wap-Myc;Wap-Cre;E2f3 +/loxP mice, the deletion efficiencies of the E2f3 loxP allele were 31.6% and 32.5%, respectively. These numbers are about 25% lower than the deletion efficiencies of the stop cassette in the Rosa26 LSL-lacZ reporter allele in similar settings (Figure 4d ). More importantly, E2f3 deletion efficiencies were further reduced to 22.5% in tumors derived from Wap-Myc;Wap-Cre;E2f3 −/loxP mice, and to 12.1% in tumors derived from MMTV-ErbB2;Wap-Cre;E2Ff3 −/loxP mice (Figure 4d ). Taken together, these data strongly suggest that there is a selection pressure against E2f3 −/− mammary epithelial cells to form tumors in both oncogenic models, and such pressure is even higher in tumors with ErbB2 over-expression than in those with Myc over-expression. Considering that the majority of tumors (~88% for MMTV-ErbB2;Wap-Cre;E2f3 +/loxP mice and ~77% for Wap-Myc;Wap-Cre;E2f3 +/loxP mice) are not deleted for E2f3, the delay of tumor onset in those mice depicted in Figure 3a was most likely substantially underestimated.
Deletion of E2f3 leads to a marginal reduction of proliferation in pre-tumor state mammary epithelial cells
The tumor-free curves presented in Figure 3a , together with the qPCR data showing that E2f1 and E2f3a are preferentially up-regulated in mammary carcinomas with ErbB2 or Myc over-expression, raise the possibility that E2F1 and E2F3 are critical downstream effectors of the ErbB2-Ras-Cyclin D1 oncogenic signaling axis in the mammary epithelium. Considering that E2Fs are intimately involved in controlling cellular proliferation, (11, 39, 46) a biological process that often becomes aberrant during tumorigenesis, we investigated whether loss of individual E2fs affects cellular proliferation of mammary epithelium with oncogene-expression. Since loss of E2f1 and E2f3 led to the most significant delays of tumor onset in MMTV-ErbB2 mice, we focused on determining whether loss of E2f1 or E2f3 in pre-tumor state MMTV-ErbB2 mice affects proliferation of mammary epithelial cells from mice that have gone two pregnancy/lactation cycles. As shown in Figure 5a , while the percentages of Ki67-positive cells were very similar between MMTV-ErbB2 mice and MMTV-ErbB2;E2f1 −/− mice, there was a marginally significant decrease in percentages of Ki67-positive cells in MMTV-ErbB2;Wap-Cre;E2f3 −/loxP mice than in ErbB2 mice (3.6% vs. 6.5%; p = 0.045). Importantly, there was no significant difference in percentages of Ki67-positive cells between tumors with wild-type E2fs and those deficient for E2f1, E2f2, or E2f3 (Figure 5b and 5c ). The fact that E2f3 −/− tumors had similar numbers of Ki67-positive cells as observed in the control or E2f3 heterozygous tumors suggests that either E2f3 is indispensable for ErbB2-and Myc-induced tumor cells to proliferate, or E2f3 −/− tumor cells bypass the requirement of E2f3 for maintaining normal levels of proliferation through compensational mutations.
Characterization of mammary tumors deficient for various E2fs
To investigate whether deletion of various E2fs affects the biology of mammary tumors with either oncogene over-expression, we first compared the histology of tumors deficient for E2f1, E2f2, or E2f3 to those with wild-type E2fs. As reported before, mouse mammary carcinomas resulted from ErbB2 over-expression were solid tumors, while tumors resulted from Myc over-expression were more glandular (Figure 6a ). However, careful examination of H&E-stained sections of primary tumors revealed no major microscopic changes in tumors deficient for various E2fs (Figure 6a , and data not shown), suggesting that deletion of individual E2fs did not change the biological behavior of the mammary tumors.
Previous studies demonstrated substantial functional redundancies among various E2F activators(11) or repressors(47) for cellular proliferation and/or mouse development. To determine whether mammary tumors deficient for individual E2fs experience any compensational up-regulation of other members of E2f activators, we used qPCR to measure expression levels of various E2f genes in tumors deficient for E2f1, E2f2, or E2f3. As shown in Figure 6b , there was no obvious compensational up-regulation of any E2f activators in tumors deficient for E2f1, E2f2, or E2f3 compared to tumors with wild-type E2fs, suggesting that mammary tumors in mice deficient for individual E2fs arose without compensational up-regulation of other E2f activators. Interestingly, de-regulation of some repressor E2fs was observed in tumors lacking certain E2Fs (Supplementary Figure 1) .
We previously showed that E2F1-3 control E2F target gene activation and cellular proliferation through a p53-dependent negative feedback loop. (48) 
Discussion
Previous studies have demonstrated that cyclin D1 is an essential component of the ErbB2/Ras (but not the Wnt/Myc) oncogenic pathway in the mouse mammary epithelium. (41) However, the role of specific E2Fs in ErbB2/Ras-or Wnt/Myc-mediated mammary tumorigenesis remains largely unknown. In this study, we found that E2f3a is up-regulated in the majority of mouse and human primary mammary carcinomas with ErbB2 or Myc over-expression (Figure 1 ), raising the possibility that E2F3a is a critical downstream effector of the ErbB2-or Myc-oncogenic pathway. Indeed, loss of E2f3 (and E2f1 to a lesser extent) leads to significant delays of mammary tumor onset in both oncogenic models (Figure 3a and 3b) . Importantly, Southern blot analysis of the final tumors revealed a strong selection against E2f3 −/− cells from developing mammary tumors as the majority of the tumors (~77% for Myc mice and ~88% for ErbB2 mice) retained a functional E2f3 loxP allele ( Figure 4) ; Wap-Cre-mediated deletion efficiency for a Rosa26-LSL-lacZ reporter allele is about 40% in both oncogenic models, whereas the E2f3 deletion efficiency is reduced to ~23% in tumors with Myc-over-expression, and is further reduced to about 12% in tumors with ErbB2 over-expression (Figure 4) . Taken together, these data strongly suggest that E2F3 is a critical mediator for the ErbB2-and Myc-triggered mammary carcinogenesis. Since the E2f3 locus encodes E2F3a and E2F3b isoforms and since the E2f3 knockout mouse line used in the present study lacks both isoforms, it remains to be determined whether E2F3a or E2F3b or both play important roles in mediating ErbB2-or Myc-triggered mammary tumorigenesis. Considering that E2F3a is believed to be an activator E2F, whereas E2F3b a repressor E2f, and that E2f3a is up-regulated in the majority of mouse and human primary mammary carcinomas with ErbB2 or Myc over-expression, we postulate that E2F3a is the primary isoform in modulating oncogene-induced mammary tumorigenesis. It is interesting to note that loss of E2f2 in mice with Myc over-expression accelerates mammary tumor development, consistent with its tumor suppressor role that was recently demonstrated in Myc-induced T-cell lymphomagenesis (35) and epithelial tumorigenesis. (37) The fact that deletion of E2f2 in mice accelerates Myc-induced mammary tumorigenesis but does not affect ErbB2-mediated mammary tumorigenesis suggests that the tumor suppression role of the E2f2 locus is most likely dependent on Myc oncogene activation.
It has been well documented that E2F activators are critical for normal cellular proliferation. (11, 46) Several recent studies using in vivo mouse models also implicated E2F activators in mediating oncogene-induced tumorigenesis. For example, while loss of E2f1 impairs the ability of Myc to induce T cell lymphomas,(34) loss of E2f2 accelerates Myc-induced lymphomagenesis. (35, 36) In the present study, we showed that E2F activators are important downstream effectors in mediating ErbB2-and Myc-induced mammary tumorigenesis, since loss of E2f1 or E2f3 led to significant delays of tumor onset in both oncogenic models, and loss of E2f2 accelerated tumor onset in the Wap-Myc model. While our data supports a tumor suppressor role of E2f2 in the context of Myc activation that was recently postulated in several mouse tumor models, (35) (36) (37) it is seemingly inconsistent with a recent report suggesting a tumor promoting role of E2f2 in a MMTV-Myc-driven mammary tumor model. Breast cancer represents the highest estimated new cancer cases and the second leading cause of cancer mortality in woman in the United State.(50) Unfortunately, breast cancer therapy has been hampered by limited knowledge on the molecular bases of the disease. Although activation/over-expression of ERBB2 or MYC has been found in up to 30% of breast cancer patients, the critical effector(s) induced by either oncogene remains unknown. In the present studies we identified E2F3 (and E2F1 to a lesser extent) as an important downstream effectors in mediating ErbB2-and Myc-triggered mammary tumorigenesis, and E2F2 as a tumor suppressor in mediating Myc-triggered mammary tumorigenesis. Future studies to delineate the mechanistic link between E2Fs and the Myc and ErbB2 oncogenes in mouse mammary tumor development would allow us to link pathway deregulation with potential therapeutic strategies for breast cancer. Such studies may provide critical insights in developing customized molecular therapies and/or combinatorial therapies of cancers based on individual patients' defined genetic alterations of particular signaling pathways or molecules.
Materials and Methods
Mice and PCR-based genotyping
MMTV-Neu mice (42) and Wap-Myc mice(43) were obtained on a FVB background, whereas Wap-Cre, Rosa26-LSL-lacZ, E2f1 −/− , E2f2 −/− , and E2f3 −/loxP mice were backcrossed to a FVB background for five or six generations to minimize the heterogeneity arose from mixed genetic backgrounds. All mice for tumor studies had gone through two pregnancy/lactation cycles to maximize the Wap-Cre expression. Genotypes of mice were determined by standard PCR of genomic DNA isolated from mouse tails. All mice were maintained in a barrier facility in accordance with standards established by the Institutional Animal Care and Use Committee at the Ohio State University. Mice at end points were euthanized by CO 2 asphyxiation. Mammary glands or mammary tumors were either snap-frozen for molecular analysis, or fixed in 10% formalin for histological and immunocytochemical analyses.
Whole mounts, histology and immunofluorescence staining
Mammary glands number 4 or number 9 were dissected and mounted onto glass slides. After being fixed at 4°C overnight in a Carnoy's fixative, the whole mount glands were stained overnight with carmine following a standard protocol. For histological analysis, 5 um paraffin-embedded sections were stained with hematoxylin and eosin (H&E). To assess lacZ expression patterns, we stained whole mount glands/tumors or 5 um paraffin-embedded sections with X-gal using standard X-gal staining protocols. For immunofluorescence staining, 5 um sections were de-paraffinized in xylene, sequentially rehydrated, and rinsed in de-ionized water. Antigen retrieval was performed using a DAKO Target Retrieval solution. Slides were incubated with primary antibodies against Ki67 (BD Biosciences, 1:100 dilution) and a fluorescence-conjugated secondary antibody (Alexa 488 from Molecular Probes, 1:500 dilution), and counterstained with DAPI.
Southern blot analysis
Genomic DNA isolated from mammary tumors was digested with EcoRV. Southern blot was carried out as previously described.(11)
Real-time quantitative RT-PCR (qPCR)
Frozen mammary tissues were used for total RNA isolation using TRIzol (Life Technologies). Human patient samples were obtained and processed in accordance with the Institutional Review Board approval at the Ohio State University. Reverse transcription of 2-5ug of total RNA was performed to generate cDNA using Superscript III reverse transcriptase (Invitrogen). qPCR was carried out in triplicates using a SYBR-Green-based system (BioRad) and a BioRad iCycler. Data were analyzed using the ΔCt method, and were normalized by the expression levels of Gapdh.
Statistical analysis
Pairwise comparisons on Kaplan-Meier tumor-free curves were performed using the Logrank test. For each comparison, we used a Bonferonni adjusted alpha level to determine statistical significance. To assess tumor growth, we used an electronic caliper to measure palpable tumors once a week for six weeks after tumor onset. Tumor volumes were estimated by calculating 0.4 × L × S 2 where L was the longest dimension and S was the shortest dimension. Tumor growth was analyzed by two way analysis of variance (ANOVA) for repeated measures over the course of the 6-week measurements and then by unpaired ttest to compare values at six weeks. Average number of palpable tumors was determined at six weeks following the onset of the first palpable tumor of each mouse and was tested for statistical significance by unpaired t-test. All other pairwise statistical analyses were done using unpaired T-test.
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